This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Verano Holdings (OtherVRNO), Community Health (CYH) and Glaukos (GKOS)

Tipranks - Tipranks - Tue Apr 14, 6:34AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Verano Holdings (VRNO), Community Health (CYH) and Glaukos (GKOS).

Claim 30% Off TipRanks

Verano Holdings (VRNO)

In a report released today, Aaron Grey from Alliance Global Partners reiterated a Buy rating on Verano Holdings, with a price target of C$5.00. The company’s shares closed last Friday at $1.14, close to its 52-week low of $0.58.

According to TipRanks.com, Grey is ranked 0 out of 5 stars with an average return of -7.1% and a 32.9% success rate. Grey covers the Consumer Goods sector, focusing on stocks such as Village Farms International, Turning Point Brands, and Honest Company. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verano Holdings with a $3.64 average price target.

See today’s best-performing stocks on TipRanks >>

Community Health (CYH)

In a report released today, David S Macdonald from Truist Financial reiterated a Hold rating on Community Health. The company’s shares closed last Friday at $3.15, close to its 52-week low of $2.53.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 9.5% and a 57.1% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

Community Health has an analyst consensus of Hold, with a price target consensus of $3.55, which is an 12.0% upside from current levels. In a report issued on March 30, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $3.00 price target.

Glaukos (GKOS)

William Blair analyst Steven Lichtman maintained a Buy rating on Glaukos today. The company’s shares closed last Friday at $116.40.

According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 12.1% and a 50.7% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Sight Sciences, and Cooper Co. ;'>

Currently, the analyst consensus on Glaukos is a Strong Buy with an average price target of $132.78, which is a 10.0% upside from current levels. In a report issued on April 7, Citi also maintained a Buy rating on the stock with a $135.00 price target.

Read More on VRNO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).